
























issue	 of	 transducing	 T-cells	 with	 a	 transgenic	 TCR	 is	 the	 pre-existing	 expression	 of	 TCRs	 in	 the	
recipient	cells.	These	endogenous	TCRs	compete	with	the	transgenic	TCR	for	surface	expression	and	
allow	mixed	 dimer	 formation.	Mixed	 dimers,	 formed	 by	mispairing	 between	 the	 endogenous	 and	
transgenic	TCRs,	may	harbor	autoreactive	specificities.	To	circumvent	these	problems,	we	designed	a	
system	 where	 the	 endogenous	 TCR-β	 is	 knocked	 out	 from	 the	 recipient	 cells	 using	 CRISPR/Cas9	
technology,	 simultaneously	 with	 transduction	 with	 a	 cancer-reactive	 receptor	 of	 choice.	 This	 TCR	
replacement	 strategy	 resulted	 in	 markedly	 increased	 surface	 expression	 of	 transgenic	 αβ	 and	 γδ	
TCRs,	which	in	turn	translated	to	a	stronger,	and	more	polyfunctional,	response	of	engineered	T-cells	




redirection	 of	 CD4+	 and	 CD8+	 T-cells	 against	 a	 panel	 of	 established	 blood	 cancers	 and	 primary,	
patient-derived	 B	 acute	 lymphoblastic	 leukemia	 blasts	 compared	 to	 standard	 TCR	 transfer.	 Our	






remissions,	 after	 adoptive	 cell	 transfer	 in	 patients	 with	 cancers	 resistant	 to	 other	 therapeutic	
interventions1–6.	The	genetic	re-targeting	of	T-cells	to	cancer	can	be	achieved	either	by	transduction	




Vertebrate	 TCRs	 exist	 as	 heterodimers	 composed	 either	 of	 αβ	 or	 γδ	 TCR	 chains.	 Conventional	 αβ	
TCRs	recognize	short	antigenic	peptides	presented	by	major	histocompatibility	complex	(MHC)	I	or	II	
molecules	(by	CD8+	and	CD4+	T-cells,	respectively).	The	targets	recognized	by	human	γδ	T-cells	tend	
to	 be	 predominantly	 proteins	 expressed	 on	 cell	 surface	 in	 context	 of	 a	 generalized	 cellular	 stress,	
including	malignant	transformation9.	A	notable	exception	to	this	rule	is	recognition	of	pyrophosphate	
metabolites	 from	 the	 mevalonate	 pathway	 (henceforth	 referred	 to	 as	 phosphoantigens)	 by	 the	
predominant	peripheral	blood	subset	of	γδ	T-cells	which	express	TCRs	comprised	of	the	Vγ9	and	Vδ2	
chains10.	Since	there	is	no	evidence	for	MHC	restriction	of	γδ	T-cells,	and	their	targets	are	expressed	
on	 a	 broad	 range	 of	 cancers,	 γδ	 TCRs	 offer	 an	 exciting	 potential	 for	 pan-population	
immunotherapy11.	
The	use	of	a	 transgenic	TCR	 in	primary,	patient-autologous	T-cells	 is	hampered	by	 the	presence	of	
pre-existing,	endogenous	TCRs	within	these	cells.	Expression	of	TCR	at	the	cell	surface	requires	the	
formation	of	a	ternary	complex	with	the	CD3	components	of	this	receptor	which	constitute	a	limiting	
factor	 for	 surface	 expression	 of	 the	 antigen-binding	 chains	 of	 the	 TCR.	 As	 a	 result,	 successful	
expression	of	transduced	TCR	at	the	cell	surface	requires	that	it	must	successfully	compete	with	the	
endogenous	TCR	chains	for	CD3	association12.	In	addition,	there	is	also	potential	for	the	formation	of	
hybrid	 TCRs	 due	 to	 mis-pairing	 of	 endogenous	 and	 transduced	 TCR	 chains	 (so-called	 mixed	 TCR	
dimers).	 Thus,	 a	 transduced	T-cell	 has	potential	 to	express	 four	distinct	TCRs,	only	one	of	which	 is	
desired.	 Mixed	 TCR	 dimers	 can	 also	 exhibit	 unpredictable,	 and	 potentially	 dangerous,	 target	
specificities,	and	have	been	shown	to	cause	fatal	autoimmunity13.	
Several	 methodologies	 have	 been	 explored	 to	 overcome	 the	 issue	 of	 TCR	 competition	 and	
mispairing.	 These	 approaches	 include	 generation	 of	 affinity-enhanced	 TCRs14,	 engineering	 of	
mutations	 to	 improve	 the	 pairing	 of	 transgenic	 TCRs15,	 or	 overexpression	 of	 CD3	 components12.	
Affinity-enhanced	 TCRs	 have	 shown	 high	 rates	 of	 objective	 clinical	 response	 since	 even	 a	 small	
number	of	 functional	TCR	molecules	 is	 sufficient	 to	convey	antigen-specific	 signaling	due	 to	 super-
physiological	 activity16.	 However,	 affinity-enhanced,	 engineered	 TCRs	 have	 bypassed	 the	 rigors	 of	
thymic	selection	and	have	potential	 to	react	 to	self	antigens.	 Indeed,	unanticipated	cross-reactivity	
by	an	affinity-enhanced	MAGE	A3-specific	TCR	with	an	epitope	from	titin	caused	fatal	autoreactivity	
in	both	patients	that	were	treated	with	T-cells	expressing	this	TCR17,18.	
Here	we	 aimed	 to	 enhance	 the	 functionality	 of	natural	 TCRs	 during	 TCR	 gene	 transfer	 of	 primary	
CD8+	and	CD4+	T-cells	by	simultaneous	knockout	of	the	endogenous	αβ	TCR	during	transfer	of	a	TCR	
of	 choice.	 This	 approach	enhanced	 the	expression	of	 the	 transduced	TCR	at	 the	T-cell	 surface	 and	
resulted	in	TCR	transductants	that	displayed	substantially	improved	antigen	sensitivity.	In	particular,	
we	 focused	 on	 leveraging	 broadly	 cancer-reactive	 γδ	 TCRs	 in	 the	 TCR	 transfer	 system	 as	 this	
approach	 can	 be	 used	 irrespective	 of	 patient	 HLA	 type.	 T-cells	 transduced	 with	 this	 system	were	





The	 following	 cell	 lines	 were	 purchased	 from	 ATCC	 and	 cultured	 according	 to	 manufacturer’s	
recommendations:	 Jurkat	 E6.1,	 Molt-3,	 KBM7,	 K562,	 THP-1,	 U266,	 TK6.	 The	 primary	 B-acute	
lymphoblastic	 leukemia	 (B-ALL)	cells	 (HP,	VB,	BV,	KÖ,	CM,	PH)	were	cultured	 in	defined	serum-free	
media	 as	 described	 previously19,20.	 B	 lymphoblastoid	 cell	 line	 (LCL)	 146	 was	 generated	 by	 EBV	
infection	of	peripheral	mononuclear	 cells21	 (PBMC)	obtained	 from	a	healthy	donor.	Primary	B-cells	
and	T-cells	were	 isolated	 from	PBMC	based	on	CD19	or	CD4	expression,	 respectively,	and	used	 for	













3rd	 generation	 lentiviral	 transfer	 vector	 pELNS	 (kindly	 provided	 by	 James	 Riley,	 University	 of	
Pennsylvania,	PA).	The	pELNS	vector	contains	rat	CD2	(rCD2)	marker	gene	separated	from	the	TCR	by	

















µg/ml	 polybrene	 (Santa	 Cruz	 Biotechnology).	 T-cells	 that	 had	 taken	 up	 the	 virus	were	 selected	 by	
incubation	 with	 2	 µg/ml	 puromycin	 (Life	 Technologies)	 and	 magnetic	 enrichment	 with	 α-rCD2	 PE	
antibody	 (clone	 OX-34,	 Biolegend)	 followed	 by	 α-PE	 magnetic	 beads	 (Miltenyi	 Biotec).	 14	 d	 post	




and	 the	 following	antibodies:	 rCD2	FITC	 (Biolegend),	pan-αβ	TCR	PE,	pan-γδ	TCR	APC,	and	CD4	PE-
Vio770	 and	 CD8	 APC-Vio770	 (where	 applicable;	 all	 from	Miltenyi	 Biotec).	 Mel13	 transduced	 cells	
were	also	stained	with	a	cognate	tetramer	(HLA-A2	refolded	in-house	with	the	EAAGIGILTV	epitope)	
according	 to	 the	 optimized	 tetramer	 staining	protocol29.	 For	 characterization	of	 the	differentiation	
phenotype	 of	 the	 transduced	 T-cells,	 the	 following	 antibodies	 were	 used:	 PD-1	 PE,	 CCR7	 PerCP-
Vio770,	 CD45RA	 PE-Vio770,	 CD45RO	 FITC,	 and	 CD27	 APC	 (all	 from	 Miltenyi	 Biotec).	 All	 cell	 lines	
tested	were	stained	with	BTN3	PE	antibody	(Biolegend),	with	or	without	zoledronate	pre-treatment.	
For	Jurkat	activation	assay,	cells	were	incubated	with	antigen	for	16	h	and	subsequently	stained	for	
CD69.	 For	 intracellular	 cytokine	 staining,	 T-cells	were	 incubated	 for	 5	 h	with	 target	 cell	 lines,	 and	
stained	for	CD107a	(BD	Biosciences),	tumor	necrosis	factor	(TNF)α	and	interferon	(IFN)γ,	according	to	
manufacturer’s	 recommendation	 (all	 from	 Miltenyi	 Biotec).	 Cells	 were	 simultaneous	 stained	 for	
combinations	of	surface	markers	rCD2,	CD3,	CD4	and	CD8	as	required.	Events	were	acquired	on	FACS	





and	 then	 co-incubated	 with	 T-cells	 at	 various	 effector	 to	 target	 (E:T)	 ratios	 for	 4	 h,	 as	 described	
before29.	Cell	lysis	was	calculated	according	to	the	formula	below:	
%𝑙𝑦𝑠𝑖𝑠 = 𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑒𝑥𝑝𝑒𝑟𝑖𝑚𝑒𝑛𝑡𝑎𝑙	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑚𝑎𝑥𝑖𝑚𝑢𝑚	51𝐶𝑟	𝑟𝑒𝑙𝑒𝑎𝑠𝑒 ×100%	
Enzyme	linked	immunosorbent	assay	(ELISA)	
Briefly,	30,000	T-cells	were	co-incubated	with	90,000	target	cells	for	16	h,	and	the	supernatant	was	
harvested.	 The	 concentration	 of	 macrophage	 inflammatory	 protein	 (MIP)1-β,	 TNFα	 or	 IFNγ	 in	








Lentiviral	 transduction	of	primary	T-cells	 is	greatly	enhanced	when	the	cells	are	actively	dividing	 in	
response	 to	 TCR	 and	 co-stimulatory	 signals31.	 To	 incorporate	 this	 enhancement	 and	 produce	 a	
simple,	 time-efficient	 methodology	 that	 could	 be	 applied	 with	 many	 existing	 TCR	 transduction	
systems	we	activated	T-cells	in	the	presence	of	two	separate	lentiviral	populations,	one	encoding	the	
TCR	 of	 choice	 as	 a	 transgene,	 the	 other	 CRISPR/Cas9	 targeting	 the	 endogenous	 (but	 not	 codon-
optimized)	 TCR-β	 constant	 region	 (trbc1	 and	 trbc2)	 as	 described	 in	 Materials	 and	 Methods.	 Four	
guide	RNAs	(gRNAs)	targeting	TCR-β	were	designed	and	showed	>90%	knockout	efficiency	in	Jurkat	T-
cell	leukemia	line	(Supplementary	Figure	1A).	gRNA	1	was	selected	for	use	in	primary	T-cells	due	to	





ready	 comparison	 between	 different	 donors	 and	 different	 transduction	 conditions	 (TCR	 only	 or	
TCR+CRISPR).	 Following	 lentiviral	 transduction,	 transduced	 cells	 were	 selected	 by	 magnetic	 or	
fluorescence-based	 sorting	 and	 culturing	 with	 puromycin,	 where	 applicable,	 followed	 by	
conventional	 T-cell	 expansion	 protocol	 (Figure	 1B).	While	 the	 selection	 of	 transduced	 cells	 by	 rat	
CD2-based	 purification	 and	 puromycin	 treatment	 resulted	 in	 nearly	 90%	 decrease	 in	 cell	 number	
(Supplementary	Figure	2A),	the	selected	cells	were	then	capable	of	expanding	to	the	same	extent	as	
untransduced	 cells	 for	 at	 least	 five	 consecutive	 expansions	 with	 allogeneic	 feeders	 and	 PHA	
(Supplementary	 Figure	 2B).	 Notably,	 transduction	 efficiency	 with	 TCR-bearing	 lentivirus	 was	




when	 cells	 were	 co-transduced	 with	 TCR	 and	 CRISPR/Cas9	 in	 all	 donors	 tested,	 showing	 high	




TCR	 antibody	or	 a	 cognate	Mel13	 tetramer,	HLA-A2:EAAGIGILTV),	 co-transduction	with	 the	CRISPR	
vector	resulted	in	dramatically	enhanced	expression	of	the	transduced	TCR	in	all	donors	tested	(up	to	
10-fold	increase	in	mean	fluorescence	intensity,	as	well	as	a	distinct	shift	of	histogram	peak;	Figure	
2).	High	 level	 of	 expression	of	 the	 transgenic	αβ	TCR	 in	double	 transduced	 cells	 further	 confirmed	
that	TCR-β	targeting	gRNA	was	unable	to	cleave	the	codon	optimized	receptor,	and	that	the	presence	






for	 γδ20	TCR,	 and	a	HLA-A2+	melanoma	cell	 line	 for	Mel13	TCR),	 and	measured	 the	percentage	of	
cells	 expressing	 a	 marker	 of	 cytotoxicity	 CD107a,	 and	 two	 cytokines	 interferon	 (IFN)γ	 and	 tumor	
necrosis	factor	(TNF)α.	The	response	of	TCR+CRISPR	transduced	T-cells	was	markedly	stronger	than	
that	 of	 cells	 transduced	 with	 only	 TCR	 (Figure	 3A	 and	 Supplementary	 Figure	 3).	 Up	 to	 90%	 of	
TCR+CRISPR	transduced	cells	expressed	at	least	one	activation	marker	in	response	to	target	cells,	and	
most	 of	 these	 cells	 expressed	 all	 three	 markers	 tested	 for,	 indicating	 a	 strong,	 polyfunctional	
response	 to	 antigen.	 Conversely,	 less	 than	 10%	 and	 40%	 of	 cells	 transduced	 only	 with	 γδ20	 and	
Mel13	TCR	respectively	were	capable	of	mounting	a	response	to	the	target	cells	-	with	only	a	small	




downregulating	 the	 transgenic	 TCR	 upon	 stimulation	 with	 the	 cognate	 antigen	 (Supplementary	
Figure	 4).	 Importantly,	 the	 untransduced	 and	 single/double	 transduced	 cells	 showed	 similar	
terminally	 differentiated	 effector	 memory	 phenotype33,	 plausibly	 resulting	 from	 CD3/CD28	 bead	
expansion,	but	no	signs	of	T-cell	exhaustion,	in	terms	of	PD-1	expression34		(Supplementary	Figure	5).	
TCR	replacement	improves	the	sensitivity	to	antigen	of	a	γδ	TCR	by	several	orders	of	magnitude	
T-cells	 require	 a	 given	 copy	 number	 of	 antigen	 to	 be	 present	 on	 target	 cells	 in	 order	 to	mount	 a	
successful	 response,	 thus	 defining	 the	 antigen	 sensitivity.	 While	 antigen	 sensitivity	 may	 be	
manipulated	in	case	of	αβ	T-cells	by	affinity	maturation	of	the	TCR14	so	that	it	can	robustly	respond	to	
a	 very	 limited	number	 of	 antigen	 copies35,36,	 no	 such	 technology	 has	 been	developed	 for	 γδ	 TCRs.	
Therefore,	we	decided	to	investigate	if	increasing	the	copy	number	of	γδ	TCR	on	transgenic	T-cells	by	
CRISPR/Cas9	 knockout	 of	 endogenous	 TCRs	 would	 increase	 the	 sensitivity	 to	 the	 cognate	 antigen	
HMBPP	 ((E)-4-Hydroxy-3-methyl-but-2-enyl	 pyrophosphate)	 by	 TCR-transduced	 cells.	 In	 parallel	we	
tested	 the	model	 proxy	 system	 for	 studying	 the	 role	 of	 TCR	 in	 target	 cell	 recognition;	 namely	 the	
Jurkat	T-cell	leukemia	line9.	We	measured	T-cell	response	to	the	antigen	in	terms	of	MIP-1β	secretion	






respectively).	More	 importantly,	 TCR-only	 transduced	 CD8+	 cells	 were	 only	 slightly	 more	 sensitive	
than	 Jurkat	 cell	 line,	 and	well	 over	 a	 thousandfold	 less	 sensitive	 than	 the	 T-cell	 clone.	 In	 contrast,	
TCR+CRISPR	transduced	cells	showed	a	similar	degree	of	antigen	sensitivity	as	the	parental	clone,	and	
were	 >50,000	 or	 >5,000	more	 sensitive	 than	 Jurkat	 or	 single	 transduced	 T-cells,	 respectively.	 The	
improvement	in	antigen	sensitivity	observed	with	Mel13	TCR+CRISPR	transduced	T-cells	compared	to	
Mel	13	TCR-only	transduced	T-cells	was	more	modest	than	for	γδ20	TCR	(~10-fold	greater	sensitivity	
in	 terms	 of	 MIP-1b	 production;	 Supplementary	 Figure	 6B	 and	 C).	 Importantly,	 the	 improvement	
observed	 with	 Mel13	 TCR+CRISPR	 T-cells	 extended	 to	 superior	 cytotoxic	 activity	 against	 HLA-A2+	
melanoma	targets	compared	to	cells	transduced	with	Mel13	TCR	only	(Supplementary	Figure	7).	
Endogenous	TCR	knockout	enhances	recognition	of	hematological	malignancies	via	a	γδ	TCR	
Vγ9Vδ2	 TCRs	 are	 known	 to	 recognize	 metabolites	 of	 the	 mevalonate	 pathway	 in	 context	 of	
butyrophilin	3A1	molecule42–44.	The	mevalonate	pathway	is	often	dysregulated	in	cancer	cells45,	and	
can	 be	 further	 modulated	 by	 aminobisphosphonates	 such	 as	 clinically	 approved	 zoledronate46.	
Vγ9Vδ2	T-cells	and	TCRs	thus	have	the	potential	to	target	multiple	different	cancer	types.	Therefore,	
we	first	tested	the	cytotoxic	activity	of	γδ20	TCR-transduced	cells	against	an	LCL	line	derived	from	the	
same	donor	 as	 the	 parental	 T-cell	 clone.	 In	 line	with	 the	 polyfunctionality	 profile	 described	 above	
(Figure	 3)	 TCR+CRISPR	 transduced	 CD8+	 cells	 were	 able	 to	 exhibit	 stronger	 cytotoxic	 activity,	
especially	at	 low	effector:target	(E:T)	ratios	(26%	vs.	4%	at	0.8	E:T,	Figure	5A)	 to	LCL	pre-incubated	
with	zoledronate.	No	cytotoxicity	was	observed	without	zoledronate	pre-treatment,	even	in	case	of	
the	 parental	 T-cell	 clone,	 thus	 indicating	 that	 the	 endogenous	 accumulation	 of	 mevalonate	
metabolites	in	that	cell	line	was	not	sufficient	to	trigger	T-cell	activation.	
Since	 Vγ9Vδ2	 T-cells	 do	 not	 require	 CD8/CD4	 co-receptors	 for	 target	 recognition,	 we	 then	
investigated	the	potential	of	TCR	replacement	system	to	redirect	both	CD8+	and	CD4+	T-cell	subsets	
to	 a	 panel	 of	 hematological	 malignancies.	We	 tested	 the	 ability	 of	 single	 (γδ20	 only)	 and	 double	
transduced	(γδ20	+	CRISPR)	T-cells	to	undergo	activation	and	cytokine	secretion	(TNFα	and	IFNγ)	 in	







expressing	 an	 almost	 undetectable	 level	 of	 BTN3	 on	 the	 surface	 (Supplementary	 Figure	 9A).	 No	
reactivity	of	γδ20	TCR	transduced	cells	(with	or	without	TCR-β	CRISPR)	was	observed	against	freshly	





recipient	 T-cells	 has	 limited	 the	 clinical	 use	 to	 highly	 competitive/high	 affinity	 αβ	 TCRs.	 Here	 we	
demonstrate	 that	cancer-specific	αβ	or	γδ	TCRs	 that	do	not	compete	well	with	 recipient	TCRs,	and	
therefore	 exhibit	 weak	 functional	 activity,	 can	 be	 efficiently	 used	 to	 redirect	 recipient	 T-cells	 to	
cancer	 if	combined	with	simultaneous	knockout	of	endogenous	TCR-β.	The	resultant	engineered	T-






To	 date,	 there	 have	 been	 several	 reported	 attempts	 to	 combine	 endogenous	 TCR	 knockout,	 using	
zinc	 finger	 nucleases48,49,	 transcription	 activator-like	 effector	 nucleases50–53	 or	 CRISPR/Cas954,	 with	
redirecting	 the	 T-cells	 to	 cancer,	 in	 most	 cases	 via	 CARs.	 This	 is	 the	 first	 report	 demonstrating	
successful	 redirection	 of	 primary	 T-cells	 with	 a	 pan-cancer	 reactive	 γδ	 TCR	 in	 combination	 with	
endogenous	 TCR-β	 knockout.	We	 showed	 that	 removal	 of	 the	 endogenous	 TCR-β	 chain	 leads	 to	 a	
striking	 increase	 of	 surface	 expression	 of	 transgenic	 αβ	 and	 γδ	 TCRs	 that	 translates	 into	 a	 much	
stronger	response	of	engineered	T-cells	to	cancer	lines.	While	it	has	recently	been	shown	by	Eyquem	
et	al.	that	CAR	insertion	into	the	TCR	locus	is	beneficial	due	to	limiting	and	controlling	CAR	expression	
by	 physiological	 means,	 thus	 preventing	 premature	 exhaustion,	 the	 antigen	 binding	 kinetics	 and	
affinity	of	natural	TCRs	differ	significantly	from	that	of	CARs,	and	therefore	high	copy	number	of	TCRs	
on	 the	 cell	 surface	 appears	 more	 desirable55.	 	 Indeed,	 CRISPR+TCR	 transduced	 T-cells	 exhibited	 a	







used	 in	 research	 such	 as	 Jurkat	 cells,	 or	 in	 the	 clinic	 (primary	 T-cells)	 are	 up	 to	 several	 orders	 of	
magnitude	 lower	than	that	of	the	parental	T-cell	clone,	and	that	the	sensitivity	of	the	 latter	can	be	
accurately	replicated	by	combining	TCR	transfer	with	endogenous	TCR	knockout	(TCR	replacement)	
in	 primary	 T-cells.	 Apart	 from	 having	 implications	 for	 designing	 more	 effective	 TCR-based	
immunotherapies,	 this	 result	 indicates	 that	 TCR	 replacement	 is	 preferable	 to	 TCR	 transfer	 for	
functional	 characterizations	 of	 TCRs	 of	 interest	 especially	 where	 these	 TCRs	 compete	 poorly	 with	
endogenous	 TCRs	 for	 surface	 expression	 or	 have	 a	 relatively	 low	 affinity	 for	 cognate	 antigen.	 This	
approach	 should	 also	 enable	 detailed	 analysis	 of	 TCR	 recognition	 in	 the	 absence	of	 parental	 T-cell	
clones.	Such	TCRs	may	come	from	T-cells	that	display	poor	growth	characteristics	(e.g.	as	a	result	of	
cancer-mediated	 T-cell	 exhaustion57),	 or	 directly	 from	 high	 throughput	 sequencing	 of	 TCR	
repertoires58.	 One	 can	 also	 envisage	 that	 primary	 T-cells	 transduced	 with	 a	 TCR	 of	 unknown	
specificity	 but	 not	 expressing	 the	 endogenous	 TCRs	 could	 be	 used	 for	 high-throughput,	 whole-
genome	screens28	to	identify	new	TCR	ligands,	and	therefore	new	potential	therapeutic	targets.	
γδ	 T-cells	 offer	 an	 attractive	 tool	 for	 cancer	 immunotherapy,	 due	 to	 their	 ability	 to	 recognize	
ubiquitously	 expressed	 targets	 and	no	 evidence	of	MHC	 restriction.	 This	 feature	 allows	 such	 γδ	 T-
cells	 to	 respond	 to	 cancer	 from	 any	 individual	 and	 also	 eliminates	 the	 risk	 of	 graft	 versus	 host	
disease59.	To	date,	the	majority	of	clinical	trials	utilizing	γδ	T-cells	have	focused	on	the	predominant	





objective	 clinical	 responses	 in	 a	 fraction	 of	 patients	 with	 non-Hodgkin	 lymphoma,	 multiple	
myeloma60	 and	 AML62	 demonstrating	 the	 potential	 of	 γδ	 T-cell	 based	 immunotherapies	 for	
hematological	 malignancies.	 	 However,	 the	 therapeutic	 success	 of	 γδ	 T-cell	 immunotherapies	





desirable	 T-cell	 subset	 (for	 instance,	 T	 memory	 stem	 cells)	 thereby	 potentially	 allowing	 improved	
host	engraftment	and/or	function67.	We	propose	that	using	a	defined	γδ	TCR	transferred	to	patient’s	
T-cells	in	combination	with	the	knockout	of	endogenous	αβ	TCRs	could	be	a	therapeutically	beneficial	
strategy.	 Indeed,	 TCR+CRISPR	 T-cells	 showed	 a	markedly	 stronger	 response	 (in	 terms	of	 TNFα	 and	




T-cell	mediated	 recognition	of	 cancer	 cells	 and	plays	 a	direct	 anticancer	 role69,70.	No	on-target	off-
tumor	reactivity	of	γδ20	TCR	transduced	cells	was	observed	against	primary,	aminobisphosphonate-
treated	 B-cells,	 T-cells	 or	 whole	 PBMC,	 in	 line	 with	 multiple	 clinical	 trials	 indicating	 that	
aminobisphosphonate	 treatment	 (with	 or	 without	 infusion	 of	 ex	 vivo	 expanded	 γδ	 T-cells)	 was	
generally	well	tolerated	without	severe	adverse	effects	(reviewed	in	11).	It	should	be	noted,	however,	
that	 even	with	 using	 the	 TCR	 replacement	 technology	 for	 generation	of	 Vγ9Vδ2	 TCR	 transgenic	 T-
cells,	the	patients	will	most	likely	require	bisphosphonate	treatment	for	efficient	cancer	sensitization,	
in	addition	 to	adoptive	 transfer	of	 TCR	engineered	T-cells.	 The	 increasing	 clinical	 experience	 in	 co-
administering	aminobisphosphonates	and	Vγ9Vδ2	T-cells62,71–74	will	undoubtedly	 facilitate	designing	
of	clinical	trials	testing	the	efficacy	of	Vγ9Vδ2	TCR	transgenic	T-cells.	We	therefore	believe	that	the	
TCR	 replacement	 technology	 described	 here	 would	 be	 of	 use	 in	 fundamental	 and	 translational	
research	where	 it	 could,	 for	 instance,	 be	 utilized	 to	 discover	 ligands	 of	 clinically	 relevant	 TCRs.	 In	
addition,	 this	 kind	 of	 approach	 has	 potential	 for	 developing	 a	 new	 generation	 of	 TCR-based	
immunotherapies,	 provided	 the	method	 is	 optimized	 for	 the	 clinical	 scale,	 based	on	 the	wealth	of	
experience	 in	 generating	 therapeutic	 CAR	 T-cells.	 Widespread	 clinical	 application	 of	 gene	 editing	
technology	seems	 imminent,	as	demonstrated	by	 the	 recent	 success	of	 the	off-the-shelf	allogeneic	
CAR19	 T-cells	 in	 inducing	 remission	 of	 B-ALL	 in	 infants53.	 In	 summary,	 it	 seems	 likely	 that	 TCR	































































































































































































Figure	 1.	 Construct	 design	 and	 validation	 for	 transduction	 of	 primary	 T-cells.	 (A)	 Schematic	
representation	of	transgenes	cloned	into	pELNS	vector	(top)	or	lentiCRISPRv2	vector	(bottom).	EF-1α	
-	 elongation	 factor-1	 alpha	 promoter,	 U6	 -	 RNA	 polymerase	 III	 promoter,	 pac	 -	 puromycin	 N-
acetyltransferase,	EFS	-	short	EF-1α	promoter.	(B)	Timeline	for	transduction	and	selection	of	primary	
T-cells.	 (C)	 Graphical	 representation	 of	 TCR	 expression	 on	 primary	 T-cells	 transduced	 with	 pELNS	
vector,	 with	 and	 without	 lentiCRISPRv2	 vector	 (top).	 Grey	 molecules	 represent	 endogenous	 TCR	
chains	while	blue	ones	represent	transduced	TCR	chains.	The	histograms	below	show	endogenous	αβ	
TCR	expression	 in	 three	donors	 (grey	–	untransduced,	blue	–	 transduced	only	with	a	γδ	TCR,	 red	–	
transduced	with	 a	 γδ	 TCR	 and	 CRISPR),	 as	 well	 as	 a	 representative	 unstained	 control	 (black).	 The	




donor	 PBMC	 is	 markedly	 increased	 in	 presence	 of	 CRISPR/Cas9	 specific	 for	 endogenous	 TCR-β.	
Histograms	 represent	 staining	of	 transduced	CD8+	cells	with	a	pan-γδ	TCR	antibody	 (left)	or	with	a	




Figure	 3.	The	 functional	 response	 to	 target	 cell	 lines	 is	 significantly	 increased	 in	 CD8+	 T-cells	 co-
transduced	with	 TCR	 and	 CRISPR/Cas9	 specific	 for	 endogenous	 TCR-β.	 (A)	Polyfunctionality	 plots	
representing	the	response	of	transduced	and	untransduced	T-cells	 in	comparison	to	the	parental	T-
cell	 clone.	 Top	 row	 shows	 the	 response	 to	 a	 B	 LCL	 line	 pre-incubated	 with	 zoledronate	 by	 cells	
transduced	with	 the	γδ20	TCR.	Bottom	row	shows	 responses	 to	an	HLA-A2+	melanoma	cell	 line	by	
cells	 transduced	with	the	Mel13	ab	TCR.	Only	viable	CD3+	cells	were	 included	 in	 the	analysis	while	
the	gates	 for	 cells	positive	 for	 a	 given	 function	were	 set	based	on	appropriate	 fluorescence	minus	
one	 and	 biological	 controls.	 Representative	 data	 from	 two	 independent	 experiments	 and	 three	
donors	 are	 shown.	 (B)	 The	 response	of	 transduced	 T-cells	 to	 target	 cell	 lines,	 in	 terms	of	 CD107a,	













unstimulated	 cells,	 and	assuming	 the	maximum	value	 as	 100%.	 The	EC50	 values	were	 calculated	 in	
GraphPad	 Prism	 software	 by	 non-linear	 regression	 curve	 fitting.	 (B)	 EC50,	 represented	 as	 molar	




cancer	 lines	 than	with	 standard	 transduction	 techniques.	 (A)	 4	 h	 cytotoxicity	 of	 transduced	 CD8+	
cells,	 as	well	 as	 parental	 γδ20	 T-cell	 clone,	 against	 an	 untreated	 (empty	 symbols)	 or	 zoledronate-
pretreated	(filled	symbols)	γδ20	donor-autologous	B	LCL.	Representative	data	are	shown	from	three	
donors	 tested	 in	 two	experiments	 carried	out	 in	duplicate.	 (B)	 TNFα	 secretion	by	 transduced	CD8+	
(top)	or	CD4+	(bottom)	T-cells	after	overnight	co-incubation	with	a	panel	of	established	blood	cancer	
lines	of	diverse	 lymphoid	and	myeloid	origin,	or	patient-derived	B	ALL	cells.	Cancer	cells	were	pre-
incubated	 with	 zoledronate	 for	 24	 h	 before	 co-incubation	 with	 T-cells.	 TNFα	 secretion	 was	
normalized	 by	 subtracting	 TNFα	 produced	 by	 T-cells	 alone,	 and	 by	 cancer	 cells	 alone.	 No	 specific	
TNFα	 secretion	 by	 T-cells	 was	 observed	 in	 absence	 of	 zoledronate	 pre-treatment.	 Representative	
data	are	shown	from	three	donors	and	two	experiments	carried	out	in	duplicate.	
	
Figure	 6.	 Increase	 of	 γδ	 TCR	 expression	 by	 TCR-β	 knock-out	 does	 not	 enhance	 the	 targeting	 of	
normal	cells	by	engineered	T-cells.	Normal	cells	were	isolated	from	peripheral	blood	of	three	healthy	
donors	(PBMC	isolation	followed	by	magnetic	pullout	of	CD19+	B-cells	or	CD4+	T-cells)	and	incubated	
with	50	μM	zoledronate	 (where	 indicated).	On	 the	 following	day	after	 isolation,	 the	 cells	were	 co-
incubated	with	transduced	T-cells	for	16	h,	followed	by	quantification	of	secreted	TNFα	or	IFNγ.	The	
concentration	of	secreted	cytokines	was	normalized	by	subtracting	the	values	from	T-cells	incubated	
























































































































































































































































































































































Supplementary Figure 1. Design and validation of gRNAs targeting trbc loci. (A) Expression of the
endogenous αβ TCR-CD3 complex on T-cell leukemia line Jurkat E6.1, untransduced (wt) and
transduced with 4 gRNAs targeting trbc gene segments (gRNA1-4). Numbers on dot plots indicate
percentage of cells expressing αβ TCR-CD3 complex. (B) Alignment of tested gRNAs to trbc1, trbc2
and codon-optimized (c.o.) trbc sequence used in transgenic αβ TCRs. Protospacer adjacent motif
(PAM) is shown in red while blue highlight indicates nucleotide match between gRNA and trbc. gRNA



























































































Supplementary Figure 2. The kinetics and efficacy of lentiviral transduction of primary T-cells. (A)
T-cells (5×105 cells per condition) were isolated on day 0 and plated with CD3/CD28 beads. The
cells were transduced with TCR only or TCR and CRISPR lentiviruses on day 1, and cultured until day
9, followed by magnetic pullout of rCD2+ cells which were then plated with 2 μg/ml puromycin
(TCR+CRISPR only). Puromycin selection was carried out until day 14 when the transduced cells (or
a 5×105 untransduced cells) were expanded in presence of allogeneic irradiated feeders and PHA.
The cells were counted every 2-4 days by trypan blue exclusion. (B) Following the initial selection,
transduced or untransduced T-cells were expanded with allogeneic feeders and PHA every 14-28
days. The viable cells were counted after the expansion. (C) γδ20 transduced T-cells (with or
without TCR-β CRISPR) were stained for rCD2 and αβ TCR on day 9 after isolation from peripheral
blood (prior to any form of selection). Mean and standard deviation from three donors are shown.
AB
Supplementary Figure 3. Functional response of TCR-transduced CD8+ T-cells shown as individual
functions (IFNγ, CD107a, TNFα). The response of (A) γδ20 TCR-transduced CD8+ T-cells to LCL or
LCL pre-incubated with zoledronate or (B) Mel13 TCR-transduced T-cells to a HLA-A2+ melanoma.
Only viable CD3+ cells were included in the analysis while the gates for cells positive for a given
function were set based on appropriate fluorescence minus one and biological controls. Numbers
on dot plots refer to percentage of cells positive for a given function. Representative data from

















































































































































































Supplementary Figure 4. TCR-CD3 complex undergoes downregulation upon antigen stimulation.
γδ20 TCR transduced CD8+ T-cells and untransduced control cells were activated for 5 h with pan T-
cell stimulus PHA or γδ20 TCR specific stimulus zoledronate (zol; in presence of an LCL cell line).
Following incubation, cells were stained for CD3 and γδ TCR expression. Gating was performed to
include only the viable T-cells. At least 10,000 viable events were acquired. (A) CD3 and TCR
downregulation was calculated by dividing the geometric MFI of staining of stimulated by
unstimulated sample, after subtracting FMO values. Mean and standard deviation is shown. (B)
Representative staining for CD3 and γδ TCR. Numbers on histograms correspond to geometric MFI



























Supplementary Figure 5. Phenotypic profile of untransduced and transduced T-cells.
Untransduced (top row), single transduced (TCR only; middle row) or double transduced
(TCR+CRISPR; bottom row) T-cells were stained for phenotypic markers CD45RO, CD45RA, CCR7,
CD27 and PD-1. Freshly isolated PBMC were stained in parallel as a control (shown in grey).
Lymphocytes were gated based on scatter properties, followed by exclusion of doublets and dead
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CD8+ Mel13 +	CRISPR 3.2	×	10%''



























CD8+ Mel13 +	CRISPR 3.5	×	10%*
Clone Mel13 1.4 ×	10%)
Supplementary Figure 6. Antigen sensitivity of γδ20 and Mel13 TCR transduced CD8+ T-cells. (A) The
sensitivity to the titrated antigen HMBPP was measured by IFNγ production after overnight
incubation with the antigen and T2 cells used for antigen presentation. IFNγ concentration was
normalized by subtracting the values of unstimulated cells. (B) The sensitivity to the titrated peptide
EAAGIGILTV was measured by MIP-1β or (C) IFNγ production after overnight incubation with the
antigen and T2 cells used for antigen presentation. The EC50 values were calculated in GraphPad


















Supplementary Figure 7. Mel13 TCR+CRISPR CD8+ T-cells show stronger cytotoxicity
towards a melanoma cell line than Mel13 TCR-only transduced cells. 4 h cytotoxicity of
transduced CD8+ cells, as well as parental Mel13 T-cell clone, against a HLA-A2+ melanoma

























































































































































Supplementary Figure 8. T-cells transduced with CRISPR replacement show a markedly stronger
response to blood cancer lines than with standard transduction techniques. IFNγ secretion by
transduced CD8+ (top) or CD4+ (bottom) T-cells after overnight co-incubation with a panel of
established blood cancer lines of diverse lymphoid and myeloid origin, or patient-derived B ALL cells.
Cancer cells were pre-incubated with zoledronate for 24 h before co-incubation with T-cells. IFNγ
secretion was normalized by subtracting IFNγ produced by T-cells alone, and by cancer cells alone.
No specific IFNγ secretion by T-cells was observed in absence of zoledronate pre-treatment.
Representative data are shown from three donors and two experiments carried out in duplicate.
AB
Supplementary Figure 9. Butyrophilin-3 expression on cancer cell lines and normal cells. (A)
Cancer cell lines or (B) normal cells (untreated, -ve, or treated with 50 μM zoledronate, +zol) were
stained with BTN3 antibody. The numbers on histograms refer to median fluorescence intensity of
staining. Fmo, fluorescence minus one.
